TY - JOUR T1 - Super-enhancers require a combination of classical enhancers and novel facilitator elements to drive high levels of gene expression JF - bioRxiv DO - 10.1101/2022.06.20.496856 SP - 2022.06.20.496856 AU - Joseph Blayney AU - Helena Francis AU - Brendan Camellato AU - Leslie Mitchell AU - Rosa Stolper AU - Jef Boeke AU - Douglas Higgs AU - Mira Kassouf Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/06/22/2022.06.20.496856.abstract N2 - Super-enhancers (SEs) are a class of compound regulatory elements which control expression of key cell-identity genes. It remains unclear whether they are simply clusters of independent classical enhancers or whether SEs manifest emergent properties and should therefore be considered as a distinct class of element. Here, using synthetic biology and genome editing, we engineered the well characterised erythroid α-globin SE at the endogenous α-globin locus, removing all SE constituents in a mouse embryonic stem cell-line, to create a “blank canvas”. This has allowed us to re-build the SE through individual and combinatorial reinsertion of its five elements (R1, R2, R3, Rm, R4), to test the importance of each constituent’s sequence and position within the locus. Each re-inserted element independently creates a region of open chromatin and binds its normal repertoire of transcription factors; however, we found a high degree of functional interdependence between the five constituents. Surprisingly, the two strongest α-globin enhancers (R1 and R2) act sub-optimally both on their own and in combination, and although the other three elements (R3, Rm and R4) exhibit no discernible enhancer activity, they each exert a major positive effect in facilitating the activity of the classical enhancers (R1 and R2). This effect depends not simply on the sequence of each element but on their positions within the cluster. We propose that these “facilitators” are a novel form of regulatory element, important for ensuring the full activity of SEs, but distinct from conventional enhancer elements.Competing Interest StatementJef Boeke is a Founder and Director of CDI Labs, Inc., a Founder of and consultant to Neochromosome, Inc, a Founder, SAB member of and consultant to ReOpen Diagnostics, LLC and serves or served on the Scientific Advisory Board of the following: Sangamo, Inc., Modern Meadow, Inc., Rome Therapeutics, Inc., Sample6, Inc., Tessera Therapeutics, Inc. and the Wyss Institute. ER -